文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Chimeric spike mRNA vaccines protect against Sarbecoviru challenge in mice.

作者信息

Martinez David R, Schäfer Alexandra, Leist Sarah R, De la Cruz Gabriela, West Ande, Atochina-Vasserman Elena N, Lindesmith Lisa C, Pardi Norbert, Parks Robert, Barr Maggie, Li Dapeng, Yount Boyd, Saunders Kevin O, Weissman Drew, Haynes Barton F, Montgomery Stephanie A, Baric Ralph S

机构信息

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

出版信息

bioRxiv. 2021 May 11:2021.03.11.434872. doi: 10.1101/2021.03.11.434872.

DOI:10.1101/2021.03.11.434872
PMID:33758837
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7986996/
Abstract

The emergence of SARS-CoV in 2003 and SARS-CoV-2 in 2019 highlights the need to develop universal vaccination strategies against the broader subgenus. Using chimeric spike designs, we demonstrate protection against challenge from SARS-CoV, SARS-CoV-2, SARS-CoV-2 B.1.351, bat CoV (Bt-CoV) RsSHC014, and a heterologous Bt-CoV WIV-1 in vulnerable aged mice. Chimeric spike mRNAs induced high levels of broadly protective neutralizing antibodies against high-risk Sarbecoviruses. In contrast, SARS-CoV-2 mRNA vaccination not only showed a marked reduction in neutralizing titers against heterologous Sarbecoviruses, but SARS-CoV and WIV-1 challenge in mice resulted in breakthrough infection. Chimeric spike mRNA vaccines efficiently neutralized D614G, UK B.1.1.7., mink cluster five, and the South African B.1.351 variant of concern. Thus, multiplexed-chimeric spikes can prevent SARS-like zoonotic coronavirus infections with pandemic potential.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/f736efe1c7a6/nihpp-2021.03.11.434872v2-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/439934e1839d/nihpp-2021.03.11.434872v2-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/982850131f11/nihpp-2021.03.11.434872v2-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/64983107cc67/nihpp-2021.03.11.434872v2-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/313f25f78148/nihpp-2021.03.11.434872v2-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/f736efe1c7a6/nihpp-2021.03.11.434872v2-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/439934e1839d/nihpp-2021.03.11.434872v2-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/982850131f11/nihpp-2021.03.11.434872v2-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/64983107cc67/nihpp-2021.03.11.434872v2-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/313f25f78148/nihpp-2021.03.11.434872v2-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4a0/8130177/f736efe1c7a6/nihpp-2021.03.11.434872v2-f0005.jpg

相似文献

[1]
Chimeric spike mRNA vaccines protect against Sarbecoviru challenge in mice.

bioRxiv. 2021-5-11

[2]
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.

Science. 2021-8-27

[3]
A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice.

Sci Transl Med. 2022-1-26

[4]
Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice.

Cell Rep. 2023-10-31

[5]
A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice.

bioRxiv. 2021-4-28

[6]
Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice.

bioRxiv. 2023-5-23

[7]
Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates.

bioRxiv. 2023-12-19

[8]
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.

Elife. 2022-2-22

[9]
A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.

J Med Virol. 2022-9

[10]
Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.

J Virol. 2023-7-27

本文引用的文献

[1]
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.

Science. 2021-6-4

[2]
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.

Cell. 2021-4-29

[3]
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.

Cell. 2021-4-29

[4]
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.

N Engl J Med. 2021-4-15

[5]
A universal coronavirus vaccine.

Science. 2021-2-19

[6]
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.

Science. 2021-2-19

[7]
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.

Science. 2021-2-12

[8]
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

N Engl J Med. 2021-2-4

[9]
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.

Immunity. 2020-11-21

[10]
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

N Engl J Med. 2020-10-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索